DisCoVeRy trial of Verklury concluded there was no clinical benefit in hospitalised patients with COVID 19.-Gilead Sciences
The phase III open-label DisCoVeRy trial included patients admitted to hospital with laboratory-confirmed SARS-CoV-2 and if they had evidence of pneumonia or required oxygen. Participants were randomized to standard of care alone or in combination with remdesivir, lopinavir–ritonavir, lopinavir–ritonavir and interferon beta-1a, or hydroxychloroquine.Clinical status at day 15 measured by the WHO seven-point ordinal scale.
See; " Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase III, randomised, controlled, open-label trial".; The Lancet Infectious Diseases.Published: September 14, 2021 Florence AderMaude Bouscambert-DuchampMaya HitesNathan Peiffer-SmadjaJulien PoissyDrifa Belhadiand others.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins